Incepta Vaccine Ltd

What Incepta Vaccine Ltd does

Incepta Vaccine Ltd is a Bangladesh-based vaccine company headquartered in Tejgaon, Dhaka, with an indicated headcount of approximately 82 employees and a founding year of 2011. Its name and operating geography suggest it is part of, or affiliated with, the broader Bangladeshi pharmaceutical manufacturing ecosystem, but the input data provides no direct evidence of which specific vaccines it produces, what manufacturing platform (e.g., egg-based, cell-culture, recombinant, mRNA) it operates, or which diseases its products target. No product catalog, technology stack, regulatory approvals (e.g., WHO Prequalification, DGDA licensure), or pipeline disclosures are available in the source material.

The company's business model and revenue mechanics cannot be characterized from the available data. There are no disclosed pricing models, customer lists, distribution channels, partnership agreements, supply contracts, or go-to-market details. The source page at inceptavaccine.com returned only a verification/loading message rather than substantive company information, and no funding rounds, M&A activity, leadership team, or investor disclosures are present. The parent-company relationship is also undetermined from the input.

In short, only basic firmographic data is reliable: a Dhaka-based, 2011-founded vaccine entity of ~82 employees. Any assessment of product mix, technology, commercial traction, regulatory standing, or financials would need to be re-anchored on primary disclosures (e.g., DGDA filings, WHO PQ listings, parent-company consolidated reports) before being treated as analytical fact.

Name

Incepta Vaccine Ltd

Website

https://inceptavaccine.com

Company type

Private

Headcount range

51–100 employees

Short description

Incepta Vaccine Ltd is a Bangladesh-based vaccine company headquartered in Dhaka, founded in 2011 with approximately 82 employees. The input data does not disclose its specific vaccine portfolio, technology platform, customers, or financials beyond firmographic basics.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccine Quality, Safety & Pharmacovigilance (HLAIAEAL)

Keywords

• Vaccine manufacturing
• Biological products
• Human vaccines
• Immunization products
• Pharmaceutical manufacturing

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D

Core offering

Incepta Vaccine Ltd is a Bangladesh-based company whose name indicates it operates in the vaccine manufacturing sector. The company is headquartered in Dhaka (Tejgaon) and was founded in 2011. No additional product-level detail was available in the source data, as the company website returned only a verification/loading message.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Bharat Biotech: Indian vaccine manufacturer with a broad portfolio across inactivated, VLP, and recombinant platforms. Comparable as an emerging-market vaccine specialist competing for WHO PQ and domestic EPI contracts; closely aligned in target markets, scale ambition, and regulatory pathway.
• Incepta Pharmaceuticals: Larger Bangladeshi pharmaceutical parent/affiliate company with diversified generics and vaccine operations. Most directly comparable given shared geography, branding linkage to Incepta Vaccine Ltd, and overlapping Bangladesh pharma ecosystem positioning.
• Biological E: Indian vaccine and biologics manufacturer focused on affordable pediatric and emerging disease vaccines, with WHO PQ. Directly comparable as a mid-sized emerging-market vaccine producer targeting the same LMIC tender pipeline.
• Panacea Biotec: Indian vaccine manufacturer with a portfolio spanning polio, DPT, and newer biologicals. Comparable in scale and focus on affordable emerging-market vaccines; useful benchmark for what a sub-scale South Asian vaccine producer can achieve in PQ-supplied tenders.
• Indian Immunologicals: Indian vaccine and animal health biologics manufacturer producing both human and veterinary vaccines. Comparable as a regional vaccine platform operator with WHO-recognized facilities and PQ-graded products targeting LMIC markets.

Broad incumbents

• Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune, India. Directly comparable as a South Asian emerging-market vaccine producer serving WHO/UNICEF tenders — sets the benchmark for what a scaled regional vaccine manufacturer can achieve and is the dominant competitor for Bangladesh/LMIC supply.
• Sinovac Biotech: Chinese vaccine manufacturer with WHO PQ for several products and large emerging-market distribution. Comparable as an emerging-market headquartered vaccine producer serving LMIC demand — useful proxy for international expansion pathways from Asia.
• GSK Vaccines: Global vaccine leader with broad portfolio across pediatric, travel, and pandemic vaccines. Sets the global standard for vaccine development, regulatory, and commercial capability that any regional manufacturer including Incepta would need to compete against in higher-income markets.

Regional players

• Haffkine Bio-Pharmaceutical Corporation: Indian state-owned vaccine and biopharmaceutical manufacturer with long history of EPI vaccine production. Comparable as a government-affiliated South Asian vaccine producer operating at sub-scale relative to private peers.
• Bio Farma: Indonesian state-owned vaccine manufacturer producing EPI vaccines for domestic and OIC markets. Comparable as a national-pride vaccine producer in a neighboring South/Southeast Asian LMIC with similar ambition to serve domestic immunization programs and export regionally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/incepta-vaccine-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Incepta Vaccine Ltd